Fresenius Group Overview

Financial Results

To archive

Q2/21 Results

Fresenius raises Group earnings guidance after very strong Q2

  • Fresenius Medical Care with expected continued COVID-19 impact; patient excess mortality rates significantly reduced

  • Fresenius Kabi’s strong Emerging Markets business more than offsets persistent headwinds in North America

  • Helios Germany with gradually increasing elective treatment volumes; Helios Spain delivers outstanding sales and earnings growth based on strong activity levels and a weak prior-year quarter

  • Fresenius Vamed back to growth driven by good performance in the service business; growing order book in the project business

  • First savings from initiatives to improve efficiency already expected in 2021

Selected Key Figures Q2/2021

Sales

€ 9246 m

+8% 1

Q2/20: €8,920 m

EBIT 2

€ 1030 m

-4% 1

Q2/20: €1,123 m

Net Income 2, 3

€ 474 m

+20% 1

Q2/20: €410 m

Earnings per Share 2, 3

€ 0.85

+19% 1

Q2/20: €0.74

1 In constant currency

2 Before special items

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

Sales by business segment

 

€ in millions

 Q2/21

 Q2/20

Change

Organic
sales
growth
Currency translation effects Acqui-sitions Divesti-tures % of total sales1

Fresenius Medical Care

4,320 4,557 -5% 1% -7% 1% 0% 47%

Fresenius
Kabi

1,755 1,678 5% 7% -3% 0% 1% 19%

Fresenius Helios

2,738 2,315 18% 14% -1% 5% 0% 29%
Fresenius Vamed 556 475 17% 17% 0% 0% 0% 5%

Total

9,246 8,920 4% 6% -4% 2% 0% 100 %

1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.

Archive